EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Efficacy and tolerance of oral versus parenteral cyanocobalamin supplement in hypocobalaminaemic dogs with chronic enteropathy: a controlled randomised open‐label trial

C Dor iD, S Nixon, S Salavati Schmitz iD, J Bazelle, P Černá, S Kilpatrick, N D Harvey, M Dunning

Journal of Small Animal Practice · 2024

DOI: 10.1111/jsap.13705 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Small Animal Practice, 2024. Verfasst von C Dor und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterinary Medicine and Science, University of Nottingham, Nottingham, UK. Hauptthemen laut MEDLINE: Dog Diseases, Vitamin B 12, Vitamin B 12 Deficiency. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ADM Protexin.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Determine comparative tolerance of daily oral and weekly parenteral cobalamin supplementation, in hypocobalaminaemic dogs with chronic enteropathy. Determine whether oral is as effective as parenteral supplementation at achieving eucobalaminaemia, in hypocobalaminaemic dogs with protein‐losing enteropathy, severe hypocobalaminaemia or high canine inflammatory bowel disease activity index at inclusion. Materials and Methods Thirty‐seven client‐owned dogs with hypocobalaminaemia and clinical signs of chronic enteropathy were prospectively enrolled in three UK referral centres. Dogs were randomly allocated to daily oral for 12 weeks or weekly parenteral cobalamin supplementation for 6 weeks and one additional dose 4 weeks later. Serum cobalamin, body condition score, canine inflammatory bowel disease activity index and bodyweight were assessed at inclusion, weeks 7 and 13. Serum methylmalonic acid concentration was evaluated at inclusion and at week 13. Owners completed treatment adherence, palatability, tolerance and satisfaction questionnaires at week 13.

Results

Nineteen dogs completed the study. All dogs orally supplemented achieved normal or increased cobalaminaemia at weeks 7 and 13. There was no statistical difference in cobalamin concentration at week 13 in dogs treated with oral or parenteral supplementation, regardless of presence of protein‐losing enteropathy, severity of hypocobalaminaemia or canine inflammatory bowel disease activity index at inclusion. Serum methylmalonic acid concentration was not significantly different between oral and parenteral groups, neither were treatment adherence, satisfaction, and tolerance scores at week 13. Clinical Significance Oral is as effective and as well‐tolerated as parenteral cobalamin supplementation in hypocobalaminaemic dogs with chronic enteropathy and severe clinical or biochemical phenotypes, and should be considered as a suitable treatment option regardless of disease severity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dog DiseasesVitamin B 12Vitamin B 12 DeficiencyAnimalsDogsFemaleMaleAdministration, OralChronic DiseaseInflammatory Bowel DiseasesProspective StudiesProtein-Losing EnteropathiesTreatment Outcome

Substanzen

Vitamin B 12

Autor:innen und Institutionen

  • Department of Veterinary Medicine and Science, University of Nottingham, Nottingham, UK.
  • ADM Protexin Ltd, Lopen Head, Somerset, UK.
  • The Royal (Dick) School of Veterinary Studies and the Roslin Institute, The Hospital for Small Animals, University of Edinburgh, Edinburgh, UK.
  • Davies Veterinary Specialists, Manor Farm Business Park, Hitchin, Hertfordshire, UK.
  • Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA.
  • Idexx Laboratories, Grange House, Sandbeck Way, Wetherby, West Yorkshire, UK.

ORCID-Profile: C Dor, S Salavati Schmitz

Förderung

  • ADM Protexin

Zitieren

APA

Dor, C., Nixon, S., Salavati Schmitz, S., Bazelle, J., Černá, P., Kilpatrick, S., Harvey, N. D., & Dunning, M. (2024). Efficacy and tolerance of oral versus parenteral cyanocobalamin supplement in hypocobalaminaemic dogs with chronic enteropathy: a controlled randomised open‐label trial. Journal of Small Animal Practice. https://doi.org/10.1111/jsap.13705

Vancouver

Dor C, Nixon S, Salavati Schmitz S, Bazelle J, Černá P, Kilpatrick S, et al. Efficacy and tolerance of oral versus parenteral cyanocobalamin supplement in hypocobalaminaemic dogs with chronic enteropathy: a controlled randomised open‐label trial. Journal of Small Animal Practice. 2024. doi:10.1111/jsap.13705

BibTeX
@article{Dor2024,
  author = {Dor, C and Nixon, S and Salavati Schmitz, S and Bazelle, J and Černá, P and Kilpatrick, S and Harvey, N D and Dunning, M},
  title = {Efficacy and tolerance of oral versus parenteral cyanocobalamin supplement in hypocobalaminaemic dogs with chronic enteropathy: a controlled randomised open‐label trial},
  journal = {Journal of Small Animal Practice},
  year = {2024},
  doi = {10.1111/jsap.13705}
}
Kostenlos starten →